title: Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations.
abstract: Information on reactivation of chronic viral hepatitis infection in patients who are candidates for tumor necrosis factor alpha inhibitors (TNFi) is in a constant state of flux. We retrieved the most updated guidelines (in English) of prominent rheumatological and gastroenterological professional socienties for the mangement of chronic hepatitis B (HBV) and hepatitis C virus (HCV) infection in the context of treatment with TNFi. Subsequently, the major areas of uncertainty and absence of consensus in the guidelines were located and a secondary search for additional studies addressing those areas was performed. Based on our search we formulated a personal interpretation applicable to health care settings with virological laboratories capable of performing viral load measurements, and health systems that can support use of potent nucleoside/tide analogues in well-defined patient populations.
authors.affiliation: Pediatric Infectious Disease Unit, Soroka University Medical Center, Israel.
authors.forename: Inbal
authors.initials: I
authors.lastname: Fuchs
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Abu-Shakra
authors.forename: Emanuel
authors.initials: E
authors.lastname: Sikuler
mesh_terms: D002985:Clinical Protocols / Q000592:standards; D003424:Crohn Disease / Q000188:drug therapy*; D016174:Hepacivirus / Q000502:physiology; D006515:Hepatitis B virus / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000175:diagnosis* / Q000628:therapy / Q000821:virology; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000628:therapy / Q000821:virology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008403:Mass Screening / Q000379:methods / Q000458:organization & administration; D017410:Practice Guidelines as Topic; D012216:Rheumatic Diseases / Q000188:drug therapy*; D055502:Secondary Prevention; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D019562:Viral Load / Q000379:methods; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha